Redcare Pharmacy Faces Dual Challenges as Key Payment and New Rival Loom

Redcare Pharmacy is entering 2026 under significant strain. The MDAX-listed company’s shares have lost approximately half their value over the past twelve months, trading perilously close to the €65 mark. Management is confronting pressure from two sides: a substantial payment due in January and an aggressive new competitor targeting its core business.

Intensifying Competition from a Retail Giant

Perhaps the more critical long-term threat is a rapidly shifting competitive landscape. On December 16, dm-drogerie markt launched its “dm-med” platform, launching a direct assault on the over-the-counter medication market. The company is strategically shipping orders from the Czech Republic, a move that puts pressure on Redcare Pharmacy’s cost structure.

In a defensive response, Redcare has already opened a new logistics center in Plzeň, Czech Republic, and is increasingly focusing on the prescription medication segment where dm is not active. Despite this, market observers fear a potential price war could further erode the company’s already thin adjusted EBITDA margin, which recently stood at 2.4%.

A Major Financial Milestone Approaches

A crucial financial deadline is imminent. On January 21, 2026, the online pharmacy must make a final settlement payment of €64.5 million. This completes the refinancing of old convertible bonds that have occupied the company throughout 2025.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

Through the repurchase of bonds worth nearly €158 million and the placement of new notes maturing in 2032, Redcare has created financial breathing room. Despite the upcoming transfer, the liquidity position appears solid: as of September 30, 2025, the group held cash and cash equivalents of €265.6 million—an increase of almost 50% compared to the end of 2024. This cushion ensures continued operational flexibility.

Divergent Analyst Views and Short Seller Activity

Expert opinions on the stock are sharply divided. While UBS maintains a skeptical “Neutral” rating with a price target of €74, Deutsche Bank sees substantial upside potential with a target of €214. Doubts about the business model are reflected in a high level of short interest, with nearly 14% of the company’s shares sold short.

The next significant catalyst is expected on March 4, 2026, when Redcare publishes its 2025 annual report. Investors will scrutinize this release to assess whether the new competitive dynamics are impacting the outlook for the current year. Until then, the short-term price direction will likely be influenced by technical support at the 52-week low of €59.45.